Shr2285, the rst selectively oral fxia inhibitor in china: safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor

HIGHLIGHTS

• who: October et al. from the Dalian Medical University, China have published the research: SHR2285, the rst selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor, in the Journal: (JOURNAL) of 16/07/2021
• what: The aim of this study was to evaluate the safety, tolerability, PK and PD of SHR2285 tablets in combination with aspirin, clopidogrel or ticagrelor in healthy subjects. The study was reviewed and approved in writing by the ethics committee of Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.